1. Home
  2. TKC vs ACAD Comparison

TKC vs ACAD Comparison

Compare TKC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turkcell Iletisim Hizmetleri AS

TKC

Turkcell Iletisim Hizmetleri AS

HOLD

Current Price

$6.65

Market Cap

5.2B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.82

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKC
ACAD
Founded
1993
1993
Country
Turkey
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.4B
IPO Year
2000
2004

Fundamental Metrics

Financial Performance
Metric
TKC
ACAD
Price
$6.65
$25.82
Analyst Decision
Buy
Analyst Count
0
22
Target Price
N/A
$30.00
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
02-26-2026
02-25-2026
Dividend Yield
2.39%
N/A
EPS Growth
N/A
98.53
EPS
0.11
1.54
Revenue
$4,451,876,110.00
$1,047,118,000.00
Revenue This Year
$43.64
$15.16
Revenue Next Year
$28.36
$11.79
P/E Ratio
$24.98
$17.00
Revenue Growth
N/A
12.69
52 Week Low
$5.35
$13.40
52 Week High
$7.63
$28.35

Technical Indicators

Market Signals
Indicator
TKC
ACAD
Relative Strength Index (RSI) 78.80 43.84
Support Level $6.51 $25.25
Resistance Level $6.67 $27.22
Average True Range (ATR) 0.10 0.95
MACD 0.10 -0.13
Stochastic Oscillator 98.14 21.87

Price Performance

Historical Comparison
TKC
ACAD

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: